Sutro Biopharma price target lowered to $20 from $30 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Sutro Biopharma to $20 from $30 and keeps a Buy rating on the shares. The analyst continues to believe that while investor focus remains locked on the update of STRO-002 for patients with advanced ovarian cancer in the second half of 2022.